Michael Freeman
Stock Analyst at Raymond James
(2.98)
# 1,371
Out of 5,130 analysts
6
Total ratings
80%
Success rate
58.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Freeman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WVE Wave Life Sciences | Assumes: Outperform | $14 | $13.84 | +1.16% | 1 | Jun 11, 2025 | |
| TECX Tectonic Therapeutic | Reinstates: Outperform | $76 | $20.57 | +269.56% | 1 | Jun 11, 2025 | |
| DYN Dyne Therapeutics | Assumes: Outperform | $37 | $17.77 | +108.22% | 1 | Jun 11, 2025 | |
| IRON Disc Medicine | Reinstates: Strong Buy | $89 | $78.14 | +13.90% | 1 | Jun 11, 2025 | |
| RNA Avidity Biosciences | Initiates: Strong Buy | $65 | $72.37 | -10.18% | 1 | Jun 11, 2025 | |
| BHC Bausch Health Companies | Initiates: Market Perform | $8 | $7.41 | +7.96% | 1 | Jul 10, 2024 |
Wave Life Sciences
Jun 11, 2025
Assumes: Outperform
Price Target: $14
Current: $13.84
Upside: +1.16%
Tectonic Therapeutic
Jun 11, 2025
Reinstates: Outperform
Price Target: $76
Current: $20.57
Upside: +269.56%
Dyne Therapeutics
Jun 11, 2025
Assumes: Outperform
Price Target: $37
Current: $17.77
Upside: +108.22%
Disc Medicine
Jun 11, 2025
Reinstates: Strong Buy
Price Target: $89
Current: $78.14
Upside: +13.90%
Avidity Biosciences
Jun 11, 2025
Initiates: Strong Buy
Price Target: $65
Current: $72.37
Upside: -10.18%
Bausch Health Companies
Jul 10, 2024
Initiates: Market Perform
Price Target: $8
Current: $7.41
Upside: +7.96%